To help our patients, GB Sciences is creating a pipeline for the development of novel medicines based on our own patent-pending formulations of chemicals extracted from the Cannabis plant. GBS Global Biopharma, Inc., owned by GB Sciences, has now filed eight patent applications on new therapies that are complex mixtures of compounds derived from cannabis, and it has licensed three approved patents.

GBS Global Biopharma partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program. Our end goal is not to take these novel formulations to market ourselves, because we know our limitations. Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.

Scientific Advisory Board

The GBS Global Biopharma Scientific Advisory Board provides oversight for product development within GBS Global Biopharma’s intellectual property portfolio.

GB Sciences’ Competitive Advantages

GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.

GB Sciences’ Patient Groups

GBS Global Biopharma has filed eight provisional patent applications containing formulations to tackle neuropathic pain, neurodegenerative disorders and cardiovascular disease among others.

Biopharma Pipeline

GBS Global is creating a pipeline for the development of novel medicines.

Research Partners

Our goal is to be the perfect partner to research universities and organizations.